114 related articles for article (PubMed ID: 9631863)
1. Proposed consensus for definitions and endpoints for clinical trials of acute kidney transplant rejection.
Guttmann RD; Soulillou JP; Moore LW; First MR; Gaber AO; Pouletty P; Schroeder TJ
Am J Kidney Dis; 1998 Jun; 31(6 Suppl 1):S40-6. PubMed ID: 9631863
[TBL] [Abstract][Full Text] [Related]
2. Efficacy Endpoints Conference on Acute Rejection in Kidney Transplantation: summary report of the database.
Schroeder TJ; Moore LW
Am J Kidney Dis; 1998 Jun; 31(6 Suppl 1):S31-9. PubMed ID: 9631862
[TBL] [Abstract][Full Text] [Related]
3. Observations on recovery of renal function following treatment for acute rejection.
Gaber AO; Moore LW; Schroeder TJ
Am J Kidney Dis; 1998 Jun; 31(6 Suppl 1):S47-59. PubMed ID: 9631864
[TBL] [Abstract][Full Text] [Related]
4. Utility of standardized histological classification in the management of acute rejection. 1995 Efficacy Endpoints Conference.
Gaber LW; Moore LW; Gaber AO; First MR; Guttmann RD; Pouletty P; Schroeder TJ; Soulillou JP
Transplantation; 1998 Feb; 65(3):376-80. PubMed ID: 9484754
[TBL] [Abstract][Full Text] [Related]
5. Definitions of acute rejection and controlled clinical trials in the medical literature.
Guttmann RD; Soulillou JP
Am J Kidney Dis; 1998 Jun; 31(6 Suppl 1):S3-6. PubMed ID: 9631857
[TBL] [Abstract][Full Text] [Related]
6. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
[TBL] [Abstract][Full Text] [Related]
7. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.
Gaber AO; First MR; Tesi RJ; Gaston RS; Mendez R; Mulloy LL; Light JA; Gaber LW; Squiers E; Taylor RJ; Neylan JF; Steiner RW; Knechtle S; Norman DJ; Shihab F; Basadonna G; Brennan DC; Hodge EE; Kahan BD; Kahan L; Steinberg S; Woodle ES; Chan L; Ham JM; Schroeder TJ
Transplantation; 1998 Jul; 66(1):29-37. PubMed ID: 9679818
[TBL] [Abstract][Full Text] [Related]
8. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group.
Woodle ES; Thistlethwaite JR; Gordon JH; Laskow D; Deierhoi MH; Burdick J; Pirsch JD; Sollinger H; Vincenti F; Burrows L; Schwartz B; Danovitch GM; Wilkinson AH; Shaffer D; Simpson MA; Freeman RB; Rohrer RJ; Mendez R; Aswad S; Munn SR; Wiesner RH; Delmonico FL; Neylan J; Whelchel J
Transplantation; 1996 Sep; 62(5):594-9. PubMed ID: 8830821
[TBL] [Abstract][Full Text] [Related]
9. Management of Plasma Cell-Rich Acute Rejection in Living-Related Kidney Transplant: Role of Proteasome Inhibitor.
Abbas K; Mubarak M; Zafar MN; Musharraf W; Imam M; Aziz T; Rizvi AH
Exp Clin Transplant; 2019 Feb; 17(1):42-46. PubMed ID: 29534661
[TBL] [Abstract][Full Text] [Related]
10. Efficacy Endpoints Conference on Acute Rejection in Kidney Transplantation: review of the conference questionnaire.
Cantarovich D; Soulillou JP
Am J Kidney Dis; 1998 Jun; 31(6 Suppl 1):S26-30. PubMed ID: 9631861
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
Woodle ES; Xu D; Zivin RA; Auger J; Charette J; O'Laughlin R; Peace D; Jollife LK; Haverty T; Bluestone JA; Thistlethwaite JR
Transplantation; 1999 Sep; 68(5):608-16. PubMed ID: 10507477
[TBL] [Abstract][Full Text] [Related]
12. Quantitative assessment of the first acute rejection as a predictor of renal transplant outcome.
Ishikawa A; Flechner SM; Goldfarb DA; Myles JL; Modlin CS; Boparai N; Papajcik D; Mastroianni B; Novick AC
Transplantation; 1999 Nov; 68(9):1318-24. PubMed ID: 10573070
[TBL] [Abstract][Full Text] [Related]
13. New scoring system identifies kidney outcome with radiation therapy in acute renal allograft rejection.
Chen LM; Godinez J; Thisted RA; Woodle ES; Thistlewaite JR; Powers C; Haraf D
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):999-1003. PubMed ID: 10705023
[TBL] [Abstract][Full Text] [Related]
14. Significance of the Banff borderline biopsy.
Schweitzer EJ; Drachenberg CB; Anderson L; Papadimetriou JC; Kuo PC; Johnson LB; Klassen DK; Hoehn-Saric E; Weir MR; Bartlett ST
Am J Kidney Dis; 1996 Oct; 28(4):585-8. PubMed ID: 8840950
[TBL] [Abstract][Full Text] [Related]
15. The US multicenter double-blind, randomized, phase III trial of thymoglobulin versus atgam in the treatment of acute graft rejection episodes following renal transplantation: rationale for study design.
Schroeder TJ; Moore LW; Gaber LW; Gaber AO; First MR
Transplant Proc; 1999 May; 31(3B Suppl):1S-6S. PubMed ID: 10330958
[TBL] [Abstract][Full Text] [Related]
16. Role of renal allograft biopsy in multicenter clinical trials in transplantation.
Gaber LW
Am J Kidney Dis; 1998 Jun; 31(6 Suppl 1):S19-25. PubMed ID: 9631860
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
18. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
[TBL] [Abstract][Full Text] [Related]
19. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of OKT3 as primary therapy for histologically confirmed acute renal allograft rejection.
Kamath S; Dean D; Peddi VR; Schroeder TJ; Alexander JW; Cavallo T; First MR
Transplantation; 1997 Nov; 64(10):1428-32. PubMed ID: 9392306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
